A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
Phase 2
Completed
- Conditions
- Sarcoma, KaposiHIV Infections
- Registration Number
- NCT00002314
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ro 24-7429's inhibition of HIV-1 Tat protein in Kaposi's sarcoma pathogenesis?
How does Ro 24-7429 compare to standard antiretroviral therapy in controlling HIV replication and tumor regression in NCT00002314?
Which biomarkers correlate with Ro 24-7429's antitumor activity in HIV-related Kaposi's sarcoma patients?
What adverse events were reported in Phase II trials of Ro 24-7429 for Kaposi's sarcoma and how were they managed?
Are there combination therapies involving Ro 24-7429 and other HIV-1 Tat antagonists for Kaposi's sarcoma treatment?
Trial Locations
- Locations (2)
CARE Ctr / UCLA Med Ctr
🇺🇸Los Angeles, California, United States
New England Deaconess Hosp
🇺🇸Boston, Massachusetts, United States